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Important characteristics of chronic obstructive pulmonary dis- and fibroblasts, and increased deposition of extracellular
ease (COPD) include airway and vascular remodeling, the mo- matrix (3). In addition, advanced COPD leads to pathologic
lecular mechanisms of which are poorly understood. We as- changes in the pulmonary circulation (4, 5). At least part
sessed the role of fibroblast growth factors (FGF) in pulmonary of this is probably the result of alveolar hypoxia, which is
vascular remodeling by examining the expression pattern of
well known to cause pulmonary vasoconstriction and, if theFGF-1, FGF-2, and the FGF receptor (FGFR-1) in peripheral area
hypoxic stimulus persists, pulmonary vascular remodeling, ofof lung tissues from patients with COPD (FEV1  75%; n  15)
which increased muscularization of small arterial branchesand without COPD (FEV1 85%; n 13). Immunohistochemical
is the most striking feature (6). With sustained vasoconstric-staining results were evaluated by digital video image analysis
as well as by manual scoring. FGF-1 and FGFR-1 were detected tion of pulmonary arteries, arterioles, and veins, the medial
in vascular smooth muscle (VSM), airway smooth muscle, and vascular smooth muscle (VSM) extends distally to vessels
airway epithelial cells. FGF-2 was localized in the cytoplasm of normally devoid of smooth muscle (6). Intimal thickening
airway epithelium and in the nuclei of airway smooth muscle, due to fibrosis and emergence of smooth muscle cells within
VSM, and endothelial cells. In COPD cases, an unequivocal in- the intima of small pulmonary arterial branches has alsocrease in FGF-2 expression was observed in VSM (3-fold, P 
been reported (5). Finally, loss of the pulmonary vascular0.001) and endothelium (2-fold, P 0.007) of small pulmonary
bed by emphysema has been suggested to lead to the forma-vessels with a luminal diameter under 200 m. In addition,
tion of new vessels (6). Thus, several phenomena acting inFGFR-1 levels were elevated in the intima (1.5-fold, P  0.05).
concert in COPD result in pulmonary vascular remodeling.VSM cells of large ( 200 m) pulmonary vessels showed
increased staining for FGF-1 (1.6-fold, P  0.03) and FGFR-1 Yet little is known about the molecular mechanisms under-
(1.4-fold, P  0.04) in COPD. Pulmonary vascular remodeling, lying these processes in the context of COPD.
assessed as the ratio of -smooth muscle actin staining and A variety of growth factors and cytokines released from
vascular wall area with the lumen diameter, was increased in various sites of airway and vascular walls (VW) have the
large vessels of patients with COPD (P  0.007) and was in-
potential to contribute to the pathogenesis of vascular re-versely correlated with FEV1 values (P  0.007). Our results
modeling in COPD. In view of their important role insuggest an autocrine role of the FGF–FGFR-1 system in the
chronic inflammation, fibrosis, and repair of various tissues,pathogenesis of COPD-associated vascular remodeling.
including the lung (9), fibroblast growth factors (FGFs)
Chronic obstructive pulmonary disease (COPD) is a global may well play a pivotal role in airway and VW remodeling
health problem with increasing morbidity and mortality (1). (7, 8). FGFs exert their biologic effects via binding to four
One of the major causal factors is tobacco smoking (2). high-affinity FGF transmembrane tyrosine-kinase receptors
However, only ten percent of all smokers develop symptom- (FGFR) (9). Distinct FGF subtypes bind with different af-
atic COPD. The causes of this variability in response of the finity to the various FGFR . Alternative splicing and regu-
airways and lung parenchyma to tobacco smoke exposure lated protein trafficking further modulate the intracellular
have remained largely unclear. One of the key pathologic events and resultant response initiated by FGF ligand–
features of COPD is thickening of airway walls as a result receptor interaction (9). In the lung as well as in the vascular
of inflammation, hyperplasia of airway smooth muscle cells system, FGFs have been implicated in several pathologic
conditions. FGF-1 and FGFR-1 were shown to be upregu-
lated during the development of lung fibrosis (10). FGF-2
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Materials and Methods TABLE 1
Subject characteristics and clinical parametersSelection of Patients’ Specimens
We examined lung tissue specimens of subjects with or without Subjects without Patients with
COPD COPDCOPD. Peripheral parts of the lung tissue from current and ex-
smokers who underwent lobectomy or pneumonectomy for lung
FEV1 99  1.9 53  3.2*cancer was obtained from the Pathology Laboratories of the
dFEV1, % predicted 3  0.6 4  0.9Leiden University Medical Center, Leiden, the Netherlands, and
FEV1/FVC, %† 100  2.3 58  5.0*the Zuiderziekenhuis, Rotterdam, The Netherlands. Tissue speci-
TLC 104  2.0 108  8.8mens were taken distally from the lung hilus and predominantly
RV 115  5.5 141  15.4*consisted of parenchyma, small airways, and vasculature. All lung
Kco, % predicted 94  2.0 55  5.4*tissues were inflated by an injection syringe using formalin and
Sex (male/female) 11/2 14/1fixed for  24 h after which the tissues were further dehydrated
Age (yr) 57  3.2 59  5.0and embedded in paraffin. These tissues were subsequently pro-
Smokers/exsmokers/nonsmokers 9/4/0 12/3/0cessed for immunohistochemical staining. Based on a number of
Pack-years 33  4.7 35  5.2lung function data, patients were assigned to the groups with and
Steroid use (yes/no/unknown) 0/12/1 4/9/2without COPD (14, 15).
Group with COPD. Fifteen subjects were assigned to the COPD Definition of abbreviations: reversibility of FEV1 after 400 g salbutamol,
dFEV1; forced expiratory volume in 1 s, FEV1; forced vital capacity, FVC; carbongroup on the basis of the following parameters: forced expiratory
monoxide diffusion constant, Kco; residual volume, RV.volume in one second (FEV1)  75% of predicted value (16)
* P  0.005 versus subjects without COPD.before bronchodilation, FEV1/forced vital capacity (FVC) ratio  † FEV1/FVC is given as actual ratio in %.
75%, a reversibility in FEV1  12% of predicted after 400 g
inhaled salbutamol, and a transfer factor for carbon monoxide
(diffusion capacity) per liter alveolar volume (Kco)  80% of pre-
dicted value.
of staining obtained with a series of dilutions, which producedGroup without COPD. Thirteen subjects were assigned to the
specific and easily visible signals on paraffin sections made fromgroup without COPD on the basis of the following data; a FEV1  the same control tissue before performing the staining protocol85% before bronchodilatation, FEV1/FVC ratio  85%, and re- on all sections. To avoid day-to-day variations in staining intensit-versibility in FEV1  12% of predicted after 400 g salbutamol ies, the incubations of all specimens with each antibody were per-inhalation. To exclude accompanying lung disease leading to a
formed in one single run. Sections were deparaffinized and rehy-
restrictive function disorder, the total lung capacity of each subject
drated before incubation with specific mouse monoclonal and
included in the study was over 80% of the predicted values (16). affinity-purified antibodies against FGF-1 (1:2000 dilution), FGF-2
Clinical data of all patients were examined for possible comor- (1:200 dilution) and FGFR-1 (1:2000 dilution). The mouse IgG1
bidity and medication usage. All patients were free of symptoms antibody against human FGF-1 was raised using a synthetic peptide
of upper respiratory tract infection and none received antibiotics corresponding to the internal 61–99 amino acid sequence, whereas
perioperatively. None of the patients received glucocorticosteroids the mouse IgG2b antibody was raised against a synthetic peptide
in the 3 mo before operation; four patients received oral glucocorti- corresponding to the 16 amino acids from the C-terminus of human
costeroids perioperatively. In addition to the rigorous criteria FGFR-1, as described previously (17, 18). FGF-2 was a mouse
based on lung function parameters, microscopic exclusion criteria (IgG1 isotype) monoclonal antibody raised against human FGF-2
was also applied in the selection of patients for this study. After (molecular weight: 18–24 kD), which was procured from Transduc-
the selection based on lung function, all the lung tissues were tion Laboratories (Lexington, KY). Antihuman mouse monoclonal
subsequently examined histologically by two experienced lung pa- antibodies against -smooth muscle actin (-SMA), Ki-67 and
thologists using the following exclusion criteria: (i ) presence of FGF-2 were purchased from NeoMarkers (Clone 1A4; Fremont,
tumor in the lung tissue specimen; (ii) presence of poststenotic CA), from Biogenex (San Ramon, CA) and from Transduction
pneumonia in the specimen; (iii) fibrosis of lung tissue; and (iv) Laboratories, respectively. To block nonspecific binding, sections
obstruction of the main bronchus of the resection specimen by were preincubated with 10% normal goat serum diluted in 5%
tumor (14, 15). BSA in PBS (pH 7.4). Subsequently, sections were incubated over-
night at 4	C with the primary antibodies (FGF-1 and FGFR-1)
diluted appropriately, or for 1 h at room temperature in the case
Pulmonary Function Tests of -SMA (1:1000 dilution). Secondary biotinylated anti-immuno-
globulins (Multilink, 1:75 dilution; Biogenex) and tertiary strepta-All pulmonary function tests were performed within the 3 months
vidin conjugated alkaline phosphatase (Label 1:50 dilution; Bio-before surgery. FEV1 and FVC were measured by spirometry, total
genex) were used to enhance the detection sensitivity. Color waslung capacity, and residual volume with the closed circuit helium
developed using new fuchsin, while endogenous alkaline phospha-dilution test and the Kco using the single breath-holding technique,
tase activity was inhibited by 0.01 M levamisole.as described by Quanjer and coworkers (16). Lung function data
FGF-2 and Ki-67 immunostaining was performed on serial sec-and other patient characteristics are shown in Table 1.
tions after antigen retrieval by boiling in 10 mM citrate buffer (pH
6.0) for 10 min in a microwave oven. Sections were preincubated
with 10% normal goat serum in 5% BSA/PBS, followed by incuba-
Immunohistochemistry tion with primary antibody (1:50 dilution) overnight at 4	C. Slides
Sections of paraffin-embedded lung tissue were cut at 4 m, were rinsed in PBS, incubated for 30 min with peroxidase conju-
mounted on Super Frost Plus microscopic slides (Menzel-Gla¨ser, gated streptavidin at a dilution of 1:50 (Biogenex). Subsequently,
Braunschweig, Germany) and processed for immunohistochemis- sections were colored using 0.025% 3,3-diaminobenzidine (Sigma,
try. Serial sections were used for immunostaining of FGF-1, FGF-2, St. Louis, MO) in 0.01 molar PBS, containing 0.03% hydrogen
and FGFR-1 using human-specific antibodies. The optimal dilu- peroxide. Slides were counterstained with Mayer’s hematoxylin.
Positive controls consisted of human breast carcinoma and placen-tions for all antibodies were identified by examining the intensity
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Figure 1. Representative examples of staining intensity pattern used for visual scoring Photomicrographs depict lung tissue sections from
patients without COPD (A and C ) and with COPD (B and D ), showing FGFR-1 staining (red new-fuchsine) in vascular smooth muscle
cells. A to D show representative examples of staining intensities used for visual scoring, 0–3 respectively. Scale bar  50 m; original
magnification: 
100.
tal tissue. The optimal dilutions for all antibodies were identified inside diameter [ID]) and in the endothelium, VSM, and adventitial
area of large ( 200 m ID) pulmonary arteries.by examining the intensity of staining obtained with a series of
dilutions, which produced specific and easily visible signals on
paraffin sections derived from the same control tissue. Slides were
mounted and staining results were systematically investigated (see Video Image Analysis
below). Negative controls consisted of omission of the primary
In addition, video image analysis was performed for -SMA stain-antibody.
ing using Leica Qwin system version 3.0 (Leica B.V., Rijswijk, The
Netherlands). Twenty digital images (736 
 574 pixels) from each
section were taken using a video camera. ID of blood vessels was
Semiquantitative Analysis derived as a mean of measured vertical and horizontal diameters.
In our study, we excluded those vessels with a vertical to horizontalAll tissues were analyzed in a blinded fashion in random order by
ID ratio  3. Based on the ID, pulmonary vessels were groupedtwo independent observers who were unaware of the clinical data
into four sizes (50–100 m, 100–200 m, 200–400 m and  400of the case under study. Semiquantitative analysis was performed
m). VW area, -SMA stained area and vessel ID were measured.using an arbitrary visual scale with grading scores of 0, 1, 2, and 3
Measurements were expressed as percentages of staining per VWrepresenting no, weak, moderate and intense staining, respectively
(-SMA/VWarea), for VWarea corrected for ID (VWarea/ID) and(14, 15). Errors within and between observers were assessed by
-SMA staining, also corrected for lumen diameter (-SMAarea/ID).correlating the expression scores using Pearson’s analysis, which
indicated a very high correlation, ranging from 0.8 to 0.9. Micropho-
tographs in Figures 1A to 1D show representative examples of
Statistical Analysisstaining intensities used for visual scores 0–3, respectively. Sections
were graded for the intensity of signal expression of FGF-1, FGF-2, Data were analyzed for statistical significance using the unpaired,
two-tailed Students’ t test as well as the Mann-Whitney nonpara-and FGFR-1 in the endothelium and VSM of small (50–200 m
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metric test, when appropriate (14, 15, SPSS; SPSS Incorporated, Localization and Quantification of FGF-1 and FGF-2
Chicago, IL). The staining score data for FGF-1, FGF-2 and FGF-1 expression was detected in the media and adventitiaFGFR-1 were expressed as mean  SEM. Furthermore, FGF-1,
of large pulmonary arteries and veins, but only in the mediaFGF-2, and FGFR-1 staining scores for different vessels with ID
of small vessels. No FGF-1 staining was found in the endo-200 m and for those  200 m were correlated with FEV1 using
thelial layer of any vessels. FGF-2 was localized specificallyPearson’s correlation analysis. Furthermore, the individual FEV1
values were correlated with the vascular remodeling data (VWarea/ in nuclei of endothelial and vascular smooth muscle cells.
ID) in both the groups. Differences with P 0.05 were considered Expression of FGF-1 and FGF-2 was also observed in epi-
to be statistically significant. thelial and bronchiolar smooth muscle cells. Representa-
tive microphotographs showing the expression patterns of
Results FGF-1 and FGF-2 are presented in Figure 2. A summary
of the semiquantitative data of FGF-1 and FGF-2 immuno-Clinical Parameters
staining is presented in Figure 3. In subjects with COPD,The clinical and lung function characteristics of all subjects
we observed significantly increased (P  0.02) expressionincluded in the study are listed in Table 1. FEV1 and FEV1/
of FGF-1 in medial VSM of larger vessels, but the level ofFVC values were significantly lower in the group with
adventitial expression of FGF-1 remained unaltered (FigureCOPD than in the group without COPD (P  0.001). In
3A). In contrast to FGF-1, the expression of FGF-2 wasthe group with COPD, residual volume was increased,
elevated in the group with COPD, but only in the smallwhereas Kco was reduced (P  0.005). The subjects in the
vessels with an ID  200 m, where it was increased intwo groups did not differ significantly with respect to age,
endothelial (P  0.007) and medial smooth muscle (P total lung capacity, reversibility in FEV1, smoking status
(pack-years), or previous steroid usage (Table 1). 0.001) cells (Figure 3B).
Figure 2. Photomicrographs of lung tissue sections from patients without COPD (A and C ) and with COPD (B and D ). A and B (scale
bar  50 m; original magnification: 
100) show representative examples of FGF-1 protein staining (red new-fuchsine) in vascular
smooth muscle cells of a large vessel (ID  200 m). C and D (scale bar  100 m; original magnification: 
400) show representative
examples of nuclear FGF-2 expression (brown 3,3-diaminobenzidine) in endothelium and vascular smooth muscle cells of vessels with
ID  200 m. Arrows indicate positive nuclei.
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Figure 3. Graphic representations of FGF-1 (A ) and FGF-2 (B ) expression scores (mean  SEM) in large (ID  200 m) and small
(ID  200 m) vessels in groups without COPD (open bars) and with COPD (closed bars). * P  0.05 versus the group without COPD.
Localization and Quantification of FGFR-1 ingly, no significant differences were observed between the
groups with and without COPD in the percent of vascu-FGFR-1 immunoreactivity was detected in epithelial and
lar smooth muscle, defined as -SMA/VWarea in any vesselbronchiolar smooth muscle cells, and in the endothelium
type (Figure 7B). Proliferation of VSM cells, as evidencedand vascular smooth muscle of large and small vessels. No
from Ki-67 positivity, was observed infrequently (data notadventitial positivity for FGFR-1 was observed. Represen-
shown).tative microphotographs showing the expression pattern of
FGFR-1 are presented in Figure 4. A graphic representation Correlation with Clinical Data
of the data of FGFR-1 immunostaining is displayed in
The staining scores of FGF-1, FGF-2, and FGFR-1 expres-Figure 5. The expression of FGFR-1 was significantly ele-
sion in patients with COPD and those without COPD werevated in medial smooth muscle cells of large vessels (P 
analyzed using Pearson’s test. For FGF-1, we observed a0.04) in the group with COPD as compared with the group
weak but significant inverse correlation (r  0.39, P without COPD, whereas the staining for the receptor in
0.038) between staining score and FEV1 in the medial VSMthe intimal endothelium remained unaltered. Moreover, in
of vessels  200 m in ID (Figure 8A). In addition, therecontrast to the FGF-1 expression in small vessels in patients
was a significant inverse correlation of FGF-2 staining scoreswith COPD, we found significantly higher expression levels
in both endothelium (r  0.44, P  0.002) and medialof the receptor (P 0.05) in medial smooth muscle of small
VSM (r  0.55, P  0.0001) of vessels  200 m in IDvessels (Figure 5).
with FEV1 (Figures 8B and 8C). However, in vessels  200
m in ID, no significant correlation between FGF-2 expres-Assessment of Vascular Remodeling
sion and FEV1 was found (data not shown). Surprisingly,To examine pulmonary vascular remodeling as evidenced in
staining scores for FGFR-1 were not significantly correlatedvariations in wall thickness and muscular medial thickness,
with FEV1 (data not shown). When considering the associa-video image analysis was performed using -SMA immuno-
tion between FEV1 and medial hypertrophy (VWarea/ID ra-staining. Four separate groups with vessels of 50–100, 100–
tio), we observed a significant inverse correlation of 0.42200, 200–400 and 400 m ID, respectively, were analyzed
(P 0.007) for vessels 200 m ID (Figure 8D). However,(Figure 6). Measurements (mean  SEM) were expressed
no significant correlation could be established betweenas VWarea/ID, -SMAarea/ID, or percentage -SMA staining
FEV1 and VWarea/ID ratio for the vessels  200 m ID (rper VWarea that represents the volume fraction for smooth
0.10, P  0.10).muscle staining (-SMA/VWarea). The graphic representa-
tion of VW is presented in Figure 7. A significant increase
Discussionwas seen in VWarea/ID ratio for COPD in vessels of 100–200
m (44.2  1.9 versus 36.4  2.1, P  0.007), 200–400 m In this study we have found that COPD is associated with
an increase in the expression of FGF-2 in small pulmonary(57.9  2.4 versus 44.7  3.2, P  0.001) and  400 m
(75.6  2.6 versus 56.8  5.9, P  0.011) (Figure 7A). In vessels ( 200 m) and FGF-1 in large ( 200 m) pulmo-
nary vessels, whereas FGFR-1 is increased in both vesselvessels ranging from 50 to 100 m in ID, no differences
in VWarea/ID ratio were observed. A significant increase in types. Vascular medial thickness, assessed by video image
analysis, was significantly increased in patients with COPD-SMAarea/ID ratio was observed for COPD in the 200–400
m ID (26.7  1.9 versus 20.3  2.9, P  0.034) and  400 in pulmonary vessels of various sizes. Pearson’s correlation
analysis revealed a significant inverse correlation of FEV1m ID (38.3  2.0 versus 23.5  3.4, P  0.006) vessels,
but not in the 50–100 m and 100–200 m vessels. Surpris- with FGF-1 staining in the media of large vessels and with
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Figure 4. Photomicrographs of lung tissue sections from patients without COPD (A and C ) and with COPD (B and D ) showing FGFR-1
staining (red new-fuchsine) in vascular smooth muscle cells from large (ID  200 m; A and B ) and small (ID  200 m; C and D )
blood vessels. Scale bar  50 m; original magnification: 
100.
FGF-2 expression in both endothelium and VSM of small
vessels. In addition, an inverse correlation of FEV1 with
medial thickening was found in pulmonary vessels of larger
caliber, indicating that the degree of pulmonary vascular
remodeling is related to the severity of obstructive lung
function defect.
Several studies have commented on the importance of
structural and functional abnormalities in the pulmonary
vasculature of patients with COPD. Hypoxia is known to
induce prompt and severe vasoconstriction in the pulmo-
nary vasculature, and sustained lung tissue hypoxia, as re-
sults from obstructive lung disease such as COPD, leads to
pulmonary hypertension (4, 19). Hypoxic vasoconstriction
is considered to represent one of the major contributing
factors of pulmonary hypertension and right-sided heart
failure in COPD and other chronic pulmonary diseases (4,
19). In addition, emphysema, accompanied by loss of elastic
recoil, increased pulmonary pressure, and destruction of
part of the pulmonary microvasculature may contribute toFigure 5. Graphic representation of FGFR-1 expression scores
(mean  SEM) in large (ID  200 m) and small (ID  200 m) the increased vascular resistance observed in COPD (5, 6).
vessels in groups without COPD (open bars) and with COPD Using video image analysis, we assessed systematically
(closed bars). *P  0.05 versus the group without COPD. VW thickening in patients with COPD and non-COPD
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Figure 6. Photomicrographs of lung tissue sections from patients without COPD (A and C ) and with COPD (B and D ) showing -smooth
muscle actin staining (red new-fuchsine) in vascular smooth muscle cells from small (ID  200 m; A and B ) and large (ID  200 m;
C and D) blood vessels. Scale bar  50 m; original magnification: 
100).
cases. Wall thickness of vessels 200 m or more in diameter Wright and coworkers (5, 23) also observed a correlation
with the severity of disease in patients with mild to moderatewas increased in patients with COPD. Our results on pulmo-
nary vascular remodeling, particularly in terms of intimal COPD with intimal thickening and in those with severe
COPD with medial thickening. Similar findings on vascularand medial thickening, are in agreement with several earlier
reports (4, 5, 20–22). Furthermore, the degree of intimal abnormalities in patients with COPD were recently re-
ported by Peinado and coworkers, who showed intimal butand medial thickening was correlated with the decrease in
lung function and, hence, with the severity of the disease. not medial thickening in the vasculature of patients with
Figure 7. Graphic representations
of VW measurements (mean 
SEM) using video image analysis
in the group without COPD
(open bars) and that with COPD
(closed bars). (A ) Ratio of vascu-
lar wall area/ID (VWarea /ID) ra-
tio. (B ) Ratio of -SMAarea/
VWarea. *P  0.05 versus the
group without COPD.
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peripheral regions of the lungs of patients with COPD, we
also observed FGF-1 in adventitia and FGF-2 immunoreac-
tivity in the nuclei of medial smooth muscle and endothelial
cells, suggesting a potential role of the FGF–FGFR system
in vascular remodeling in patients with COPD.
FGF family members are implicated in tissue remodeling
in a wide variety of pathophysiologic conditions, including
systemic hypertension, ischemic heart disease, and intersti-
tial lung fibrosis (10, 12, 26, 27). Barrios and coworkers (10)
showed FGF-1 and FGFR-1 expression in experimentally
induced pulmonary fibrosis. Becerril and colleagues found
that FGF-1 expression in the lung fibroblasts results in dow-
nregulation of collagen synthesis and upregulation of col-
lagenases, which may protect against fibrosis (28). How-
ever, increased FGF-2 and FGFR-1 expression in vascular
smooth muscle cells in vitro in response to vascular injury
has been shown to be associated with extracellular matrix
remodeling, cellular proliferation, downregulation of colla-
gen type I, and upregulation of collagenase MMP-1 (29).
Our findings of upregulated FGF-1, FGF-2, and FGFR-1
expression could indicate that such compensatory mecha-
nisms are active in COPD because smoking has been sug-Figure 8. Correlation with FEV1% predicted of (A ) FGF-1 expres- gested to affect cellular viability in lungs.sion in vascular smooth muscle cells (VSM; ID  200 m), (B )
In a recent study, Singh and colleagues demonstratedFGF-2 expression in endothelial cells (EC) from small blood ves-
that increased nuclear expression of FGF-2 in vascularsels (ID  200 m), (C ) FGF-2 expression in VSM cells (ID 
smooth muscle and endothelium precedes arterial enlarge-200 m), and (D ) vascular wall area/ID (VWarea/ID). Correlation
coefficient (r ) and significance level (P value) were obtained using ment in response to increased arterial blood flow in vivo
Pearson’s linear regression analysis. (12). Though the function of high molecular weight FGF-2
in the cell nucleus remains unclear, it is believed that this
form of FGF-2 translocates to the nucleus. Moreover, Sta-
chowiak and coworkers have demonstrated colocalization
mild COPD compared with nonsmoking control subjects of FGFR-1 and FGF-2 in the nucleus of human astrocytes,
(20, 21). suggesting novel mechanisms for the action of FGF-2 (30).
We used expression of smooth muscle marker -SMA In this study, we show that FGF-2 is localized in the nucleus
(24) to investigate whether the -SMA/VWarea ratio of of endothelial and VSM cells and that its expression is
smooth muscle in the VW had changed during the progres- increased in pulmonary vessels with diameter  200 m in
sion of COPD. Surprisingly, the ratio remained unchanged. patients with COPD, indicating a role for this growth factor
Approximately 42% of cells in all vessels stained positive in vascular remodeling. We also show that in patients with
for -SMA, indicating that the increase in wall thickness COPD, the expression of FGF-2 was upregulated in vessels
could be attributed to the deposition of extracellular matrix with an ID of 200m. Bryant and coworkers (13) recently
proteins and the medial accumulation of other cells, such found that administration of FGF-2 could inhibit internal
as inflammatory cells and fibroblasts. Recently, we found luminal area decrease and wall thickening in response to
specific staining for extracellular matrix proteins, like fi- altered blood flow; furthermore, this inhibitory effect could
bronectin and collagen subtypes, in the intimal vascular be blocked by anti–FGF-2 neutralizing antibodies. Our
cells of these pulmonary vessels, indicating ongoing intimal findings suggest that FGF-2 plays an important role in the
fibrosis in patients with COPD (data not shown). Taken response to increased pressure in the pulmonary vasculature
together, the data from this study indicate that vascular of patients with COPD. Several studies on hypoxia-induced
remodeling in patients with COPD could be a contributing pulmonary hypertension have shown that increased smooth
event in the pathogenesis of pulmonary hypertension in muscle mass develops as a result of hypertrophy and hyper-
these patients. Furthermore, the observed changes in the plasia of pre-existing smooth muscle cells, or results from
intimal fibrosis as well as medial thickening could narrow differentiation of fibroblasts recruited to the media from
the vessel caliber and may eventually lead to more severe the adventitia (24, 31). It is likely that such mechanisms of
vascular obstruction in patients with COPD. vascular smooth muscle mass increase are operational in
Members of the FGF family FGF-1, FGF-2, and FGFR-1 COPD-related vascular remodeling.
are constitutively expressed in normal human lungs, particu- In vivo and in vitro data indicate that smooth muscle
larly in airway epithelium and monocytes, and are localized cells, and their cross-talk with the endothelium, myofi-
in the intima and media of pulmonary vessels (25). Pulmo- broblasts, and inflammatory cells via growth factors and
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